改变激发环境调控Ho3+离子的上转换发光特性

稀土掺杂上转换发光材料的发光特性不仅依赖于基质材料本身,而且与其激发条件密切相关.本文主要是以Ho^3+离子为研究对象,在NaYF4和LiYF4这两种不同的基质中,研究其在不同激发条件下的上转换发光特性.通过共聚焦显微光谱测试系统,对比Ho^3+离子在NaYF4和LiYF4微米晶体中的发光特性.实验结果发现:Ho^3+离子在这两种不同基质中均展现出较强的荧光发射.然而,当激发功率增加时,在单颗粒个LiYF4微米晶体中,当激发功率增加时,Ho^3+离子则发射出较强绿光及微弱的红光,红绿比变化并不明显,其蓝光发射强度也相对较弱.当激发这两种微米粉末晶体时,结果发现:Ho^3+离子均发射较强的绿光发射并伴有微弱红光发射,两种晶体中的发射特性极其相似.由此可见,在常规测试条件下,一些特殊发光现象是很难被观测到的.同时,通过对其光谱特性的分析,对Ho^3+离子的发光机理进行了研究.     

Development of an LC‐MS/MS method for determining the pharmacokinetics of clonidine following oral administration of Zhenju antihypertensive compound

Zhenju antihypertensive compound (ZJAHC) is a combined Chinese–Western medicine formula including clonidine (CLO), hydrochlorothiazide (HCT), rutin, Chrysanthemum indicum extract and pearl powder. Compared with CLO preparations, ZJAHC shows improved activities and decreased adverse effects. It is believed that the side effects of CLO are caused by its high peak plasma concentration. Hence, study of the influence of ZJAHC on the pharmacokinetic behaviors of clonidine seems essential. In present study, the plasma concentrations of CLO were determined with a liquid chromatography–tandem mass spectrometry (LC‐MS/MS) method. The MS/MS transitions monitored for clonidine and internal standard were 230.2 → 213.1 and 152.2 → 110.2, respectively. The analyte was quantified in a single run within 3 min. The pharmacokinetic study showed that the area under the plasma concentration–time curve of CLO in ZJAHC (60 µg/kg CLO) was similar to that of CLO‐HCT‐high (120 µg/kg CLO) but the peak concentration was much lower than that in CLO‐HCT‐high. ZJAHC could enhance the bioavailability without greatly increasing peak concentration of clonidine. This comprehensive effect of enhancing the bioavailability and avoiding the high peak plasma concentration for CLO might mainly result from the co‐contribution of Western medicine and traditional Chinese medicine (TCM), while the effect of TCM was stronger than that of Western medicine. Copyright © 2014 John Wiley & Sons, Ltd.     

On Fermat Diophantine functional equations,little Picard theorem and beyond

Aequationes mathematicae - We discuss equivalence conditions for the non-existence of non-trivial meromorphic solutions to the Fermat Diophantine equation $$f^m(z)+g^n(z)=1$$ with integers $$m,n\ge...     

A pH-Sensitive Zwitterionic Iron Complex Probe with High Biocompatibility for Tumor-Specific Magnetic Resonance Imaging

Accurate diagnosis of tumor characteristics, including its location and boundary, is of immense value to subsequent therapy. Activatable magnetic resonance imaging (MRI) contrast agents that respond to tumor-specific microenvironments, such as the redox state, pH, and enzyme activity, enable better mapping of tumor tissue. However, the practical application of most reported activatable agents is hampered by problems including potential toxicity, inefficient elimination, and slow activation. In this study, we developed a zwitterionic iron complex (Fe-ZDS) as a positive MRI contrast agent for tumor-specific imaging. Fe-ZDS could dissociate in weakly acidic solution rapidly, accompanied by clear longitudinal relaxivity (r₁) enhancement, which enabled the complex to act as a pH-sensitive contrast agent for tumor-specific MR imaging. In vivo experiments showed that Fe-ZDS rapidly enhanced the tumor-to-normal contrast ratio by >40 %, which assisted in distinguishing the tumor boundary. Furthermore, Fe-ZDS circulated freely in the bloodstream and was excreted relatively safely via kidneys owing to its zwitterionic nature. Therefore, Fe-ZDS is an ideal candidate for a tumor-specific MRI contrast agent and holds considerable potential for clinical translation.